Prices are updated after-hours
Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Phase 3    save search
Arcturus Announces Self-amplifying COVID-19 mRNA Vaccine Candidate ARCT-154 Meets Primary Efficacy Endpoint in Phase 3 Study
Published: 2022-04-20 (Crawled : 12:00) - biospace.com/
TAK | News | $13.23 -1.12% 0.0% 920K twitter stocktwits trandingview |
Health Technology
 | | O: 1.17% H: 0.68% C: 0.27%
JNJ | News | $148.53 -0.69% 0.18% 7.5M twitter stocktwits trandingview |
Health Technology
 | | O: 1.06% H: 1.14% C: 0.91%
ARCT 4 | $26.98 -3.4% -3.44% 270K twitter stocktwits trandingview |
Health Technology
 | | O: -20.04% H: 28.04% C: 21.44%
covid-19 arct-154 vaccine mrna phase 3
Bavarian Nordic Announces Initiation of a Global Phase 3 Clinical Trial of its RSV Vaccine Candidate in Older Adults
Published: 2022-04-20 (Crawled : 06:00) - globenewswire.com
JNJ | News | $148.53 -0.69% 0.18% 7.5M twitter stocktwits trandingview |
Health Technology
 | | O: 1.06% H: 1.14% C: 0.91%
vaccine trial phase 3 order
Actinium Pharmaceuticals, Inc. to Highlight Iomab-B Pivotal Phase 3 SIERRA Trial Data at the Transplantation & Cellular Therapy Tandem Meetings of ASTCT and CIBMTR
Published: 2022-04-19 (Crawled : 12:00) - biospace.com/
ATNM | $7.06 1.44% 0.0% 150K twitter stocktwits trandingview |
Health Technology
 | | O: 0.9% H: 11.33% C: 5.07%
trial therapy phase 3
Journal of Sexual Medicine Publishes Sexual Satisfaction Data Involving Phexxi® from Evofem's Phase 3 AMPOWER Clinical Trial
Published: 2022-04-19 (Crawled : 11:00) - prnewswire.com
EVFM | $0.0149 16.41% -16.94% 740K twitter stocktwits trandingview |
Health Technology
 | | O: -1.37% H: 4.31% C: 3.78%
phexxi trial phase 3
AMGEN ANNOUNCES POSITIVE TOP-LINE RESULTS FROM PHASE 3 STUDY OF ABP 654, BIOSIMILAR CANDIDATE TO STELARA® (USTEKINUMAB)
Published: 2022-04-18 (Crawled : 22:00) - biospace.com/
BGNE | $144.12 3.69% 3.48% 190K twitter stocktwits trandingview |
Health Technology
 | | O: -1.9% H: 0.12% C: -3.78%
AMGN | News | $273.01 -0.19% -0.17% 1.5M twitter stocktwits trandingview |
Health Technology
 | | O: -0.46% H: 0.0% C: 0.0%
stelara biosimilar positive results phase 3 topline
Entasis Therapeutics Presents SUL-DUR Topline Data from Phase 3 ATTACK Trial at ECCMID 2022 Conference
Published: 2022-04-18 (Crawled : 13:00) - biospace.com/
ETTX | $2.19 -0.46% 0.46% twitter stocktwits trandingview |
Health Technology
 | | O: 0.0% H: 0.53% C: 0.0%
conference topline trial therapeutics phase 3
Cidara Therapeutics and Mundipharma to Present Results from Global Phase 3 ReSTORE Trial of Rezafungin for the Treatment of Candidemia and/or Invasive Candidiasis at ECCMID 2022
Published: 2022-04-14 (Crawled : 13:20) - biospace.com/
CDTX | News | $12.29 19.9% 14.15% 57K twitter stocktwits trandingview |
Health Technology
 | | O: 0.24% H: 6.02% C: 2.49%
treatment trial therapeutics phase 3 candidemia
Agios Announces Publication of Phase 3 ACTIVATE Study in New England Journal of Medicine Demonstrating Benefits of PYRUKYND® (mitapivat) for Adults with Pyruvate Kinase Deficiency
Published: 2022-04-14 (Crawled : 13:00) - globenewswire.com
AGIO | $31.67 -0.44% -0.44% 640K twitter stocktwits trandingview |
Health Technology
 | | O: -0.81% H: 3.51% C: -4.58%
pyrukynd publication benefits phase 3
Marinus Pharmaceuticals Announces Publication in The Lancet Neurology of ZTALMY® (ganaxolone) Phase 3 Marigold Trial Results
Published: 2022-04-14 (Crawled : 12:00) - biospace.com/
MRNS | $1.44 0.0% 1.3M twitter stocktwits trandingview |
Health Technology
 | | O: 0.74% H: 0.0% C: -5.11%
ztalmy trial results phase 3 lancet
Esperion Announces Publication of Phase 3 Data for Bempedoic Acid in the Journal of Clinical Lipidology
Published: 2022-04-13 (Crawled : 17:00) - biospace.com/
ESPR | $2.13 1.91% 1.18% 5.2M twitter stocktwits trandingview |
Health Technology
 | | O: -0.72% H: 8.5% C: 8.14%
phase 3
Oncternal Therapeutics Deprioritizes Development of ONCT-216 to Focus Resources on Phase 3 Trial for Zilovertamab in the Treatment of Mantle Cell Lymphoma
Published: 2022-04-13 (Crawled : 13:00) - biospace.com/
ONCT | $8.545 -2.51% -0.11% 1.6K twitter stocktwits trandingview |
Health Technology
 | | O: 0.0% H: 0.0% C: -0.86%
onct-216 treatment trial therapeutics phase 3
ProKidney confirms Phase 3 program for autologous kidney cell therapy REACT®Two Phase 3 controlled trials with substantially similar design to enroll 1,200 subjects with diabetic CKD
Published: 2022-04-12 (Crawled : 19:00) - biospace.com/
DNAC 4 | $9.28 -7.2% 3.45% twitter stocktwits trandingview |
| | O: 0.1% H: 0.1% C: 0.0%
react trials enroll kidney program therapy diabetic designation phase 3
Takeda’s TAKHZYRO® (lanadelumab) Open Label Phase 3 Study Met Its Objectives in Children Ages 2 to <12 Years of Age With Hereditary Angioedema (HAE)
Published: 2022-04-12 (Crawled : 12:00) - biospace.com/
TAK | News | $13.23 -1.12% 0.0% 920K twitter stocktwits trandingview |
Health Technology
 | | O: 0.07% H: 0.47% C: -0.4%
takhzyro label children phase 3 hereditary angioedema
VistaGen and AffaMed Complete Key Regulatory Submissions for PALISADE Global Phase 3 Clinical Trial for PH94B
Published: 2022-04-12 (Crawled : 12:00) - biospace.com/
VTGN | $4.72 -2.28% -1.68% 150K twitter stocktwits trandingview |
Health Technology
 | | O: 3.01% H: 8.03% C: 1.46%
ph94 trial phase 3
Neoadjuvant Opdivo (nivolumab) with Chemotherapy Significantly Improves Event-Free Survival in Patients with Resectable Non-Small Cell Lung Cancer in Phase 3 CheckMate -816 Trial
Published: 2022-04-11 (Crawled : 15:20) - biospace.com/
BMY | $48.86 -0.27% 0.98% 14M twitter stocktwits trandingview |
Health Technology
 | | O: -0.09% H: 0.55% C: -1.54%
opdivo trial cancer phase 3 nivolumab
Veru’s Novel COVID-19 Drug Candidate Reduces Deaths by 55% in Hospitalized Patients in Interim Analysis of Phase 3 Study; Independent Data Monitoring Committee Halts Study Early for Overwhelming Efficacy
Published: 2022-04-11 (Crawled : 12:00) - biospace.com/
LLY | News | $732.2 -1.81% -0.84% 1.7M twitter stocktwits trandingview |
Health Technology
 | | O: 0.45% H: 0.21% C: -1.32%
VERU | $1.32 3.53% 3.77% 1.5M twitter stocktwits trandingview |
Health Technology
 | | O: 37.7% H: 143.24% C: 105.01%
covid-19 drug sabizabulin phase 3
Junshi Biosciences and Coherus Present Results of Phase 3 Study of Toripalimab in First Line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma at 2022 AACR Annual Meeting
Published: 2022-04-09 (Crawled : 04:20) - globenewswire.com
CHRS | $2.02 -7.34% -7.39% 630K twitter stocktwits trandingview |
Health Technology
 | Email alert Add to watchlist
treatment results phase 3
Coherus and Junshi Biosciences Present Results of Phase 3 Study of Toripalimab in First Line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma at 2022 AACR Annual Meeting
Published: 2022-04-08 (Crawled : 18:00) - globenewswire.com
CHRS | $2.02 -7.34% -7.39% 630K twitter stocktwits trandingview |
Health Technology
 | | O: -0.4% H: 3.36% C: -0.08%
treatment results phase 3
Tonix Pharmaceuticals Initiates Enrollment in the RESILIENT Study, a Potentially Pivotal Phase 3 Study of TNX-102 SL for the Management of Fibromyalgia
Published: 2022-04-07 (Crawled : 12:00) - biospace.com/
TNXP | $0.16 2.04% 1.2% 940K twitter stocktwits trandingview |
Health Technology
 | | O: 1.99% H: 8.58% C: 2.0%
tnx-102 management fibromyalgia enroll phase 3 potential
Spero Therapeutics Tebipenem Pivoxil Hydrobromide Phase 3 Data Published in The New England Journal of Medicine
Published: 2022-04-06 (Crawled : 22:00) - globenewswire.com
SPRO | $1.42 -1.05% -1.77% 110K twitter stocktwits trandingview |
Health Technology
 | | O: 1.57% H: 10.69% C: 4.64%
therapeutics phase 3
Gainers vs Losers
62% 38%

Top 10 Gainers
CSSE 4 | $0.4253 179.25% 64.77% 210M twitter stocktwits trandingview |
Consumer Services
BOF | $2.08 77.78% 41.21% 110M twitter stocktwits trandingview |

ILAG | $0.54 12.27% 40.62% 3.7M twitter stocktwits trandingview |

LICN | $0.999 78.39% 40.49% 15M twitter stocktwits trandingview |

AMST | $3.4 70.0% 39.58% 70M twitter stocktwits trandingview |
Technology Services
MTC | $3.6 60.71% 38.04% 9.1M twitter stocktwits trandingview |
Technology Services
WIMI | $1.15 58.53% 36.92% 19M twitter stocktwits trandingview |
Technology Services
AIH | $0.458 14.5% 30.92% 91K twitter stocktwits trandingview |
Health Services
WHLM | $6.25 35.87% 28.46% 700K twitter stocktwits trandingview |
Commercial Services
MULN | News | $3.77 38.1% 27.78% 13M twitter stocktwits trandingview |
Information
Your saved searches
Save your searches and get alerts when important news are released.